Grifols SA PRF PERPETUAL EUR 0.05 - Cls B GIFOF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if GIFOF is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $6.19
- Day Range
- $6.87–6.88
- 52-Week Range
- $5.58–10.21
- Bid/Ask
- $5.98 / $7.06
- Market Cap
- $4.67 Bil
- Volume/Avg
- 2,087 / 51,839
Key Statistics
- Price/Earnings (Normalized)
- 26.72
- Price/Sales
- 0.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Core
- Total Number of Employees
- 23,737
- Website
- https://www.grifols.com
Competitors
Valuation
Metric
|
GIFOF
|
CSL
|
PFE
|
---|---|---|---|
Price/Earnings (Normalized) | 26.72 | 28.43 | 15.12 |
Price/Book Value | 0.72 | 5.28 | 1.76 |
Price/Sales | 0.65 | 6.32 | 2.85 |
Price/Cash Flow | 7.47 | 32.99 | 14.43 |
Price/Earnings
GIFOF
CSL
PFE
Financial Strength
Metric
|
GIFOF
|
CSL
|
PFE
|
---|---|---|---|
Quick Ratio | 0.63 | 0.95 | 0.58 |
Current Ratio | 2.79 | 2.15 | 0.91 |
Interest Coverage | 1.31 | 7.21 | 0.74 |
Quick Ratio
GIFOF
CSL
PFE
Profitability
Metric
|
GIFOF
|
CSL
|
PFE
|
---|---|---|---|
Return on Assets (Normalized) | 1.30% | 8.11% | 4.98% |
Return on Equity (Normalized) | 4.69% | 18.17% | 10.90% |
Return on Invested Capital (Normalized) | 3.45% | 10.94% | 7.28% |
Return on Assets
GIFOF
CSL
PFE
Drug Manufacturers - General Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Xmvbqdpgwq | Wlcyj | $698.5 Bil | |
JNJ
| Johnson & Johnson | Rcmghtj | Gpsb | $359.2 Bil | |
MRK
| Merck & Co Inc | Hhqctfg | Rkwt | $323.0 Bil | |
ABBV
| AbbVie Inc | Hgjttwzmv | Yzkhx | $289.2 Bil | |
AZN
| AstraZeneca PLC ADR | Jlbtbcngbh | Gsrm | $236.3 Bil | |
NVS
| Novartis AG ADR | Lqdbnpv | Ppfr | $197.3 Bil | |
RHHBY
| Roche Holding AG ADR | Vfgczcddw | Mggjg | $192.5 Bil | |
AMGN
| Amgen Inc | Tljfgtzrm | Tslz | $167.0 Bil | |
PFE
| Pfizer Inc | Nmyqvctg | Rxy | $157.5 Bil | |
SNY
| Sanofi SA ADR | Qpqllwbp | Dlmy | $122.3 Bil |